The forecasted sales data for Cardiac Glycosides in Türkiye indicate incremental growth from 2024 to 2028. The year-on-year variations are as follows: 2025 (4.5%), 2026 (0.0%), 2027 (4.3%), and 2028 (0.0%). The compounded annual growth rate (CAGR) over the forecasted five-year period is approximately 2.27%.
Future trends to observe include potential impacts of healthcare policy changes, advancements in medical treatments, and broader economic factors influencing pharmaceutical spending. Additionally, monitoring competition and market entry by new players may affect the overall sales trajectory.
